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AbstrAct
Introduction Spondyloarthritis (SpA) is a heterogeneous 
spectrum of rheumatic diseases with either predominantly 
axial inflammatory symptoms of the spine and sacroiliac 
joints or predominantly peripheral arthritis. The two main 
entities of axial SpA (axSpA) are ankylosing spondylitis 
or non-radiographic axSpA (nr-axSpA). Tumour necrosis 
factor-α inhibitors have revolutionised the treatment 
of patients with axSpA who failed to respond to non-
steroidal anti-inflammatory drugs and physical therapy. 
Chronic pain is common in patients with SpA and may 
still persist despite the lack of signs of inflammation. 
This has led researchers to hypothesise that central pain 
sensitisation may play a role in the generation of chronic 
pain in SpA. The painDETECT Questionnaire (PDQ) is 
a screening tool developed to detect neuropathic pain 
components. The primary objective is to explore the 
prognostic value of the PDQ regarding treatment response 
in patients with axSpA 3 months after initiating a 
biological agent. Secondary aim is to evaluate the impact 
of extra-articular manifestations, comorbidities and 
patient-reported outcomes and elucidate if these factors 
influence treatment response.
Method and analysis We will include 60 participants 
(≥18 years of age) diagnosed with axSpA independent of 
main entity, who initiate or switch treatment of a biologic. 
Data will be collected at baseline and at endpoint following 
Danish clinical practice (≥3 months) of treatment with 
biologics. We will explore whether the PDQ and other 
phenotypical patient characteristics are prognostically 
important for response to biological therapy according to 
established response criteria like 50% improvement in the 
Bath Ankylosing Spondylitis Disease Activity Index (50%) 
and Ankylosing Spondylitis Disease Activity Score.
Ethics and dissemination The study is approved by 
the Region of Southern Denmark’s Ethics committee 
(S-20160094) and has been designed in cooperation 
with patient representatives. The study is registered 
at  clinicaltrials. gov (NCT02948608, pre-results). 
Dissemination will occur through publication(s) in 
international peer-reviewed journal(s).
IntroductIon
Spondyloarthritis (SpA) are a heteroge-
neous group of chronic rheumatic diseases 
with overlapping symptoms including psori-
atic arthritis (PsA), arthritis associated with 
inflammatory bowel disease (enteropathic 
arthritis), reactive arthritis, ankylosing spon-
dylitis (AS) and undifferentiated SpA.1 
Clinically, SpA can be dominated by periph-
eral joint involvement, classified as peripheral 
SpA, or by inflammatory back pain, classified 
as axial SpA (axSpA).
AxSpA is subdivided into two groups, 
referred to as non-radiographic and radio-
graphic (ie, AS), respectively. The reported 
prevalence of axSpA worldwide ranges 
from 0.01% to approximately 2.5%, and the 
incidence rates ranges between 0.48 and 
63/100 000.2 Next to the spinal and articular 
symptoms, many patients with SpA also have 
extra-articular manifestations (EAM) which 
contribute to reduced quality of life.3
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Protocol
Strengths and limitations of this study
 ► To the best of our knowledge, this is the first 
prospective cohort study in an axial spondyloarthritis 
(axSpA) population, which examines whether various 
pain phenotypes are of prognostic importance.
 ► Focus on extra-articular manifestations and 
comorbidities.
 ► Involvement of several specialties and patient 
participation.
 ► The study is adding new knowledge to the research 
field within central sensitisation in patients with 
axSpA.
 ► Heterogeneity of the study population may limit our 
ability to infer from the analyses.
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Acute anterior uveitis is a relatively common EAM in 
patients diagnosed with AS (9%) and less frequent in 
patients diagnosed with another disease among the SpA 
spectrum.4 The aetiology of SpA is complex and not 
fully understood. It is known that SpA is associated with 
multiple genes, such as HLA-B275 although the pathogen-
esis of SpA remains largely unknown. The complexity of 
the disorder indicates a multifactorial aetiology involving 
multiple biological processes or pathways.6
There has been an increasing interest in how the gut 
microbiome may be the conductor or a mediator of the 
common inflammatory pathways seen in PsA and SpA.7–9 
The intestinal microbiome is able to affect extraintestinal 
distant sites, including the joints, through immunomod-
ulation, as seen in arthritis associated with IBD.9 Certain 
types of bacterial gut infections, especially Yersinia 
enterocolitica, Shigella, Campylobacter jejuni and Salmo-
nella typhimurium infections are associated with reactive 
arthritis.10 11
Calprotectin is a protein in neutrophil granulocytes 
and macrophages and was first found and described in 
1980.12 More studies focus on calprotectin measured 
in stool and plasma in IBD and confirm their value in 
diagnosis, disease activity evaluation, effect evaluation 
and relapse monitoring.13 14 A link between SpA and IBD 
has been established for decades.15 Even without clinical 
symptoms, up to 60% of the patients with AS present 
gut inflammation at colonoscopy,16 and a recent study 
found that nearly half of the patients with SpA had micro-
scopic inflammatory lesions, with no differences between 
patients with peripheral and axSpA.17 A newly published 
study investigated the relation between serum and faecal 
levels of calprotectin and bowel histology in a SpA popu-
lation and found that elevated serum calprotectin is 
significantly linked with bowel inflammation.18
Recently, nephrolithiasis (NL) was identified as a 
common (up to 10%) and unrecognised extra-articular 
manifestation in AS.19 The risk of NL was more than 
twofold increased in patients with AS compared with the 
general population, partly explained by the altered intes-
tinal absorption and bone-remodelling. Awareness of 
EAM among clinicians is important in view of their role 
in the diagnostic process, for treatment choices and for 
health-related quality of life.
Prognosis and as a consequence also management of 
pain in patients diagnosed with axSpA is a major clinical 
challenge. Pain may still persist despite the lack of signs 
of inflammation. This has led researchers to hypothesise 
that other than nociceptive pain may play a role in the 
generation of chronic pain in axSpA (ie, fibromyalgia/
central pain sensitisation). Fibromyalgia (using the 1990 
ACR criteria for fibromyalgia) is a frequent comor-
bidity in patients  with SpA, especially in the peripheral 
forms and with a female predominance.20 Fundamental 
knowledge of nociception from deep musculoskeletal 
structures and related mechanisms of sensitisation have 
been characterised in animals, but is still lacking in clin-
ical sciences.21 Nociceptive and neuropathic components 
both contribute to pain. Since these components require 
different pain management strategies, correct pain diag-
nosis before and during treatment is highly desirable. As 
low back pain (LBP) patients constitute an important 
subgroup of chronic pain patients, a simple, patient-
based questionnaires has been developed; painDETECT 
Questionnaire (PDQ). It can determine neuropathic pain 
components both in individual patients with LBP and 
in heterogeneous cohorts of such patients, with a high 
sensitivity, specificity and positive predictive accuracy.22 
With the PDQ, the rheumatologist may have a feasible 
and prognostically useful tool to predict the possible 
treatment outcome of anti-inflammatory treatment (ie, 
individualised therapy).
rationale and hypothesis
The PDQ was developed and validated, for the purpose 
of establishing a screening tool to evaluate the likeli-
hood of a neuropathic pain component being present 
in individual patients, in 2006. A validated algorithm was 
developed to be able to calculate a score with a range 
from 0 to 38. A score ≥19 indicates that the presence 
of a neuropathic pain component is likely, whereas 
a score ≤12 indicates that it is not. A score of 13–18 is 
considered uncertain.22 23 To the best of our knowledge, 
only one small study has shown PDQ data in relation to 
axSpA.24 Their results suggest that back pain in AS is 
a complex pain condition that includes a neuropathic 
pain component.
We hypothesise that a PDQ score ≥19 at baseline is of 
prognostic importance—potentially enabling predic-
tion of a poorer patient reported treatment response 
according to the international standards—the Bath Anky-
losing Spondylitis Disease Activity Index (BASDAI), the 
Bath Ankylosing Spondylitis Functional Index (BASFI), 
Ankylosing Spondylitis Disease Activity Score (ASDAS) 
when initiating or switching biological treatment in 
patients with axSpA.
objectives
Our primary objective is to determine whether classifi-
cation from the PDQ is valuable as a prognostic factor 
for treatment response in patients diagnosed with axSpA 
initiating or switching treatment with a biological agent. 
Secondary aim is to evaluate the impact of EAM, comor-
bidities evaluated by Charlson score, and patient-reported 
outcomes and elucidate if these factors—independently 
or by interaction—influence treatment responses. All 
participants will be screened for subclinical uveitis or 
signs of previously uveitis, which will provide us with an 
estimate of the prevalence of these conditions axSpA 
comorbidities in Denmark.
Primary endpoint and key objective
The key objective is to analyse the prognostic value of the 
PDQ score on the subsequent treatment response. The 
primary endpoint is the composite proportion of patients 
having achieved a BASDAI50 response or reduction of 
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Figure 1 Participant timeline. BASDAI, Bath Ankylosing 
Spondylitis Disease Activity Index; BASFI, Bath Ankylosing 
Spondylitis Functional Index; HBAI, Harvey Bradshaw’s 
Activity Index; PDQ, pain DETECT Questionnaire; 
SCCAI, Simple Clinical Colitis Activity Index; SPARCC, 
Spondyloarthritis Research Consortium of Canada Enthesitis 
Score; VAS, Visual Analogue Scale; SF-36, 36-Item Short-
Form Health Survey.
BASDAI ≥2/10 after ≥3 months' therapy with a biological 
agent.
Key secondary objectives
1. To analyse the proportion of patients having achieved 
an improvement of ASDAS ≥1 after ≥3 months' 
therapy with a biological agent.
2. To characterise and quantify the EAM according to 
Assessment of Spondyloarthritis International Society 
(ASAS) criteria.
3. To analyse the influence of self-reported disease 
activity at baseline as predictor of on treatment 
response: Estimation of disease activity and functional 
status is evaluated using BASDAI, BASFI, ASDAS and 
36-Item Short-Form Health Survey (SF-36).
4. Change in swollen or tender joint count as determined 
by the 44-joint assessment at follow-up visit.
5. The Spondyloarthritis Research Consortium of 
Canada Enthesitis Index (SPARCC) at baseline and at 
follow-up visit.
6. The change in tender point count.
Patient participation
This study follows the European League Against Rheu-
matism (EULAR) recommendations for the inclusion of 
patient representatives in scientific projects.25 The study 
is designed with assistance from two Danish patient repre-
sentatives, Bent Duerlund (BD) and Lars Kruse Fischer 
(LKF), and both are members of the author team as well. 
They are both diagnosed with AS and were selected in 
connection with a routine care visit. They have partici-
pated in discussion of relevance of the study, ethics and 
contributed with comments to the patient information. 
The primary investigator and the patient representatives 
will meet approximately every 6th month until the study 
ends.
Method
Study design
Patients with axSpA initiating or switching antirheu-
matic treatment (biologics) in routine care will be 
included as one group in this observational study. This 
study is designed as a ‘closed cohort’ with prospective 
enrolment of patients with axSpA over time.26 Infor-
mation about the patients and their exposures will be 
collected at a single centre at two time points (figure 1), 
at baseline and after approximately 4 months of treat-
ment according to the clinical standards in Denmark. 
Examinations will be carried out consecutively on the 
same day. Furthermore, there will be an eye examination 
carried out by an ophthalmologist, within 4 weeks from 
baseline visit. Participant inclusion is expected to run 
from November 2016 to June 2018. Patients fulfilling 
the eligibility criteria (see below) will be offered partici-
pation in this study.
Participants
Participants will be recruited from The Department of 
Rheumatology, Odense University Hospital, Svendborg 
or Odense, Denmark and from The Spine Centre of 
Southern Denmark, Hospital Lillebaelt, Denmark. To be 
considered eligible for inclusion, participants must be ≥18 
years and diagnosed with axSpA and about to initiate or 
switch biological treatment. We use the ASAS criteria for 
axSpA (imaging arm) and the Modified New York criteria 
for AS, figure 2. Potential participants are identified by 
RAA, IMJH, HCH, TE, BS or site managers. The deci-
sion to initiate or change to biological treatment is taken 
collectively by senior rheumatologists at the department’s 
biologics conference where representatives of the study 
are also present. Potential participants will be given oral 
and written information about the purpose and proce-
dure of the study. Patients will be required to have normal 
results of a chest radiograph prior to the treatment with 
a biological agent and to have undergone screening for 
latent tuberculosis (TB) using the QuantiFERON TB 
Gold test. Patients in whom latent TB is discovered will 
require initiating therapy for TB prior to the first dose of 
the study agent. Patients are allowed to continue concur-
rent treatment with methotrexate (MTX), sulfasalazine, 
hydroxychloroquine, corticosteroids and non-steroidal 
anti-inflammatory drugs (NSAIDs) at stable doses during 
the study, though NSAID intake must be paused for a 
14-day period within urine and stool sampling. Further-
more, potential participants with treatment failure 
on other biologics will be considered for inclusion 
(switching). Patients, who do not wish to participate, will 
be characterised by sex and age to assess any selection 
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Figure 2 ASAS classification criteria for axial SpA. 
AS, ankylosing spondylitis; ASAS, Assessment of 
Spondyloarthritis International Society; CRP, C reactive 
protein; NSAID, non-steroidal anti-inflammatory drug; SpA, 
spondyloarthritis.
Figure 3 Overview of participant flow. SpA, 
spondyloarthritis; TB, tuberculosis; TNFi, tumour necrosis 
factor-α inhibitors.
bias. RAA and IMJH will screen potential participants 
regarding fulfilment of the inclusion criteria and none 
of the exclusion criteria. Furthermore, potential partic-
ipants will be divided into two groups, A and B: group 
A: naive to any biologics (including patients newly diag-
nosed with axSpA), group B: switching therapy, figure 3.
Inclusion criteria:
 ► Patients diagnosed with axSpA according to ASAS 
(imaging arm)
 ► ≥18 of age at time of consent
 ► Ability and willingness to give written informed 
consent and to meet the requirements of this protocol
 ► Patients must have a history of active disease and a 
BASDAI >40 (10-100) despite current or previous 
NSAIDs therapy
Exclusion criteria
 ► Age <18 years
 ► BASDAI ≤40
 ► No consent
 ► Pregnancy
 ► Active or latent TB
 ► Diagnosed HIV
 ► Diagnosed hepatitis
 ► Current or past malignant disease
 ► Recurrent or chronic infection (viral, fungal or 
bacterial)
 ► Multiple sclerosis
 ► Heart failure (New York Heart Association (NYHA) 
class III/IV)
treatment
Following the baseline examination, all enrolled partic-
ipants will be treated in accordance with the clinical 
treatment guideline developed by The Danish Council 
for the use of expensive hospital medicines (RADS). 
Currently (while writing the protocol), first-line therapy 
is a biosimilar infliximab compound (Remsima, Orion 
Pharma); infliximab is a human-murine chimeric mono-
clonal antibody directed against tumour necrosis factor 
(TNF)27 and is administrated at a dose of 5 mg/kg via 
intravenous infusion at weeks 0, 2, 6 and then every 8 
weeks. If the treatment is not tolerated, it will be stopped.
As part of clinical practice, patients are allowed to 
continue their conventional disease-modifying antirheu-
matic drugs: MTX and/or sulfasalazine. In accordance 
with Danish guidelines for intervention strategy patients 
will be treated with intra-articular glucocorticoid injec-
tions if needed during follow-up. Blood sample during 
treatment will be performed in accordance with the 
current clinical practice.
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eye examination
The eye examination will be performed by an ophthal-
mologist in accordance with normal clinical practice in 
Denmark. The following symptoms of acute anterior 
uveitis are registered: pain, redness of the globe, photo-
phobia and reduced visual acuity. Best-corrected visual 
acuity as determined by Snellen, intraocular pressure, 
slit-lamp examination and dilated fundus examination 
are performed and previous signs of anterior uveitis, 
for example, keratic precipitates and posterior synechiae 
are recorded. Ocular inflammation is graded according 
to the Standardisation of Uveitis Nomenclature working 
group recommendations.28
Variables and outcome measures
Included patients will undergo an examination 
programme to collect variables shown in table 1.
Information on1 demographic data (age, sex, height, 
weight, educational level, smoking status),2 29 clinical 
characteristics (symptom duration, duration since axSpA 
diagnosis and type of the form of clinical involvement), 
HLA-B27, family history and EAM3 activity data and 
monitoring methods (erythrocyte sedimentation rate, 
C reactive protein (CRP), Visual Analogue Scale (VAS) 
for pain and activity, morning stiffness, joint assessment, 
painful enthesis (BASDAI)),4 employment status and 
functional ability (BASFI), PDQ, tender point count 
and SF-365 comorbidity (including depression) will be 
obtained by interview and clinical examination at base-
line and follow-up visit (Charlson Comorbidity Index 
Score),6 30 we will use the Simple Clinical Colitis Activity 
Index (SCCAI) and the Harvey Bradshaw’s Activity Index 
(HBAI) regarding symptoms of inflammatory bowel 
diease (IBD).
clinical examination
A trained healthcare professional will perform the inter-
views and clinical examinations. During the study period, 
the patients will receive routine care, with prospective 
registration in DANBIO (a nationwide registry, approved 
as a clinical quality registry by the Danish National Board 
of Health), according to normal clinical practice in 
Denmark.
The SPARCC31 will be used to enthesitis count.
Assessment of pain
The PDQ has been translated into 19 different languages, 
including Danish. It is composed of questions regarding 
pain intensity (three numeric rating scales, pain course 
pattern, a pain drawing reflecting pain radiation and 
seven questions addressing somatosensory phenomena 
which the patient rates on a six-category Likert scale 
(never–very strongly). A score ranging between 0 and 38, 
based on the patient’s answers in the questionnaire, is 
calculated. For diagnostic purposes, a validated algorithm 
has been developed. A painDETECT score ≥19 indicates 
that a neuropathic pain component is likely, a score of 
13–18 is considered uncertain and a score ≤12 indicates 
that a neuropathic pain component is unlikely, resulting 
in three categories of patient pain characteristics. For a 
comprehensive description and overview of the single 
questions (items) in the questionnaire, we refer to the 
original article by Freynhagen et al.22 The tender point 
count, a part of the 1990 ACR criteria for fibromyalgia, 
where the cut-off is 11 of 18 tender points,32 will be used 
as well.
Blood, urine and stool samples
Faecal and plasma calprotectin33 and orosomucoid34 will 
be assessed at baseline and follow-up visit and will be 
considered as an indicator for intestinal inflammation. 
Furthermore, we will examine the stool for intestinal 
pathogen bacteria. A urine sample will be assessed at 
baseline and follow-up visit. Any event of NL will be regis-
tered. Any intake of NSAIDs will be paused in a 14-day 
period prior to baseline visit.
Blood samples (table 1) will be collected and anal-
ysed according to standard procedures. Blood sample 
during treatment will be performed in accordance with 
the current clinical practice. The frequency of these 
blood samples will be decided by the responsible treating 
rheumatologist depending on symptoms or signs of side 
effects. The exact number of tests and the precise time 
line for performing test may therefore deviate from the 
one scheduled in figure 3. Furthermore, a Biobank will be 
established in connection with the routine blood samples 
taken at baseline (~90 mL). The blood samples will be 
handled and registered by research laboratory techni-
cians at the laboratory department and stored at Odense 
University Hospital (in the cold store). The material  was 
collected in order to carry out analyses in connection with 
the current investigation and for future research in SpA.
Patient-reported outcomes
In the context of monitoring disease activity in 
patients  with SpA, most of the variables are based on 
patient-reported outcomes. We will use the following in 
our study:
1. The BASDAI: The BASDAI is a 6-item scale to measure 
severity of fatigue, spinal and peripheral joint pain, 
localised tenderness and morning stiffness, using the 
VAS.
2. The BASFI: The BASFI is a 10‐item scale on which 
respondents rate the degree of difficulty they have in 
performing certain tasks, using VAS from 0 (easy) to 
100 (impossible). The mean of the 10 responses is the 
BASFI score.
3. The Medical Outcomes Study SF-36 is a generic 
health status questionnaire that was developed as 
a tool to compare various aspects of health status 
across a general and broad patient population.35–37 
The SF-36 examines eight general health domains: 
physical functioning, role limitations due to 
physical health problems, bodily pain, general 
health perceptions, vitality, social functioning, 
role limitations due to emotional problems and 
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Table 1 Summary of measures to be collected
Demographics
  Sex (M/F) X
  Age (years) X
  Height (m) X
  Weight (kg) X X
  BMI (kg/m2) X X
  Education level X
  Smoking (current/previous/never) X
Disease characteristics
  Symptom duration (months) X
  Symptom duration prior to diagnosis (months) X
  Axial disease (yes/no) X
  Peripheral joint involvement (yes/no) X X
Medication
  Prior NSAID (yes/no) X
  Current NSAID at assessment (yes/no) X X
  Prior DMARD therapy (yes/no) X
  MTX dose (mg/week) X X
  Other current DMARD therapy X X
  No of previous biologics used (if any) X
  Name of current biological agent X X
  Dose of prednisolone orally at assessment (mg/week) X X
  Dose of prednisolone orally 1 week prior to assessment (mg/week) X X
  Dose of prednisolone orally 2 weeks prior to assessment (mg/week) X X
  Intra-articular glucocorticoid injections in the previous 3 months (n) X X
  Intramuscular glucocorticoid injections in the previous 3 months (mg) X X
Clinical examination
  BASMI X X
  44 tender and swollen joint count X X
  SPARCC X X
  Tender points X X
  Eye examination X X
SpA features
  Anterior uveitis, past or present (yes/no) X X
  Inflammatory bowel disease (IBD), past or present (yes/no) X X
  Psoriasis, past or present (yes/no) X X
  Psoriatic nail lesions (yes/no) X X
  Preceding infection (yes/no) X X
  Total enthesitis count X X
  Dactylitis count X X
Comorbidities X X
  Depression past or present X X
  Charlson comorbidity index score
Basic metabolic screening X X
  S-creatinin, S-calcium, S-urat, S-sodium, S-potassium X X
Urine samples X X
Continued
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Demographics
Urine-pH (dip-stick), U-calcium, U-chloride, U-potassium,
U-sodium, U-albumin, U-oxalate
X X
Patient-reported outcomes
  BASDAI, BASFI X X
  SF-36
  PDQ score X X
  HAQ score X X
  VAS fatigue, VAS pain, VAS global X X
  SCCAI X X
  HBAI X X
Blood samples X X
  HLA-B27 (positive/negative)* X X
  CRP, ESR, orosomucoid, vitamin D, immunoglobulin A, ALAT, 
alkaline phosphatise, creatinine, estimated GFR, haemoglobin, 
erythrocyte volume fraction, MCHC, MCV, leucocytes, differential count, 
thrombocyte, LDL- cholesterol, HDL-cholesterol, total cholesterol, 
serology test for shigella, plasma calprotectin, IgA†
Stool sample X
  Faecal calprotectin (mg/L) X X
  Yersinia enterocolitica, Shigella, Campylobacter jejuni, Salmonella 
typhimurium
  Chlamydia testing X X
Composite outcome measures X X
  BASDAI50 response, ΔASDAS X
X
Activity Score
*Will not be repeated if already taken.
†Will not be repeated if taken within the past 2 weeks.
BMI, body mass index; ALAT, alanine transaminase; ASDAS, ankylosing spondylitis disease; BASDAI, Bath Ankylosing Spondylitis Disease 
Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; HAQ, health assessment questionnaire CRP, C reactive protein; DMARD, 
disease-modifying antirheumatic drugs; ESR, erythrocyte sedimentation rate; GFR, glomerular filtration rate; HBAI, Harvey Bradshaw’s 
Activity Index; IgA, immunoglobulin A; MCHC, mean corpuscular haemoglobin concentration; MCV, mean corpuscular volume; LDL, low-
density lipoprotein; HDL, high-density lipoprotein, MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drug; PDQ, painDETECT 
Questionnaire; SCCAI, Simple Clinical Colitis Activity Index; BASMI, Bath Ankylosing Spondylitis Metrology Index, SPARCC, Spondyloarthritis 
Research Consortium of Canada Enthesitis Score; VAS, Visual Analogue Scale; SF-36, 36-Item Short-Form Health Survey; SpA, 
spondyloarthritis.
Table 1 Continued 
mental health. Furthermore, a physical and mental 
component summary score can be calculated. We 
will use the Danish version of SF-3638 which uses a 
4-week recall period.
4. Disease activity in patients with ulcerative colitis is 
assessed by the SCCAI—a score consisting of five 
questions regarding bowel frequency day/night, 
urgency of defecation, blood in stool and general 
well-being.39
5. Disease activity in patients with Crohn's disease is 
assessed by the HBAI—consisting of five clinical 
parameters including number of liquid stools per 
day, abdominal pain, abdominal mass, general well-
being and extraintestinal manifestations including 
arthralgia.40
exploratory outcome measures and response criteria
The response to the treatment at follow-up visit will be 
assessed by various patient-reported outcome measures. The 
BASDAI50 response criteria and ASDAS response criteria 
will be used to define treatment response. Patients who 
will not respond to TNF-α blocking therapy after 4 months 
will be classified as primary non-responders. The ASDAS 
is a composite index that assesses the disease activity. The 
ASDAS incorporates three items from the BASDAI: back 
pain (VAS), duration of morning stiffness (VAS) and pain 
of peripheral joints (VAS), as well as patient global assess-
ment of the disease activity (VAS) and CRP (mg/L).41 42 An 
ASDAS <1.3 is defined as inactive disease, ASDAS ≥1.3 to 
<2.1 is moderate disease activity, ASDAS ≥2.1 to ≤3.5 is high 
disease activity and ASDAS ≥ is very high disease activity.43 44
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StAtIStIcAl MethodS
Sample size and power considerations
For a comparison of two independent binomial propor-
tions (high vs other PDQ category) using Pearson’s χ2 
statistic with a χ2 approximation with a two-sided signif-
icance level of 0.05, a total sample size of 54 patients with 
SpA assuming that the proportion of patients with a high 
PDQ of 50% achieves a statistical power of at least 80% 
when the proportions having a BASDAI response are 15% 
and 50%, in high versus other PDQ category.
Thus, we aim to include 60 patients in total (antici-
pating 30 patients will have a PDQ>19), corresponding 
to an approximate power of 84.3% when the proportions 
with a BASDAI-response are 15% and 50%, respectively.
Statistical analysis
All descriptive statistics and tests will be reported in accor-
dance with the recommendations of the ‘Enhancing 
the QUAlity and Transparency Of health Research’ 
network:45 the STROBE Statement.26 Baseline variables 
will be described for all participants, for all continuous 
variables with means (and SDs) or medians (and IQRs) 
and for categorical variables percentages and frequencies 
will be reported. For comparisons, χ2 will be used for cate-
gorical variables and 
the Mann-Whitney test for continuous data. To assess 
the bivariate association between variables, correlation 
will be applied using Spearman's rank correlation coef-
ficient.
For the statistical testing, we will consider p values less 
than 0.05 (and 95% CIs excluding the null) to be statisti-
cally significant. Missing data at follow-up will be imputed 
by use of a non-responder assumption (applying baseline 
observation carried forward for continuous data).
To study the prognostic value of the PDQ score in 
relation to treatment response, regression models will 
be applied to study if pain measurement and/or other 
demographic/clinical measures have an impact on the 
treatment response measures and subsequently multi-
variable regression models will be applied if deemed 
necessary. According to the principles stated in the 
STROBE statement both crude and adjusted estimates 
will be reported.
discussion
The proposed study attempts to evaluate the pain mech-
anism, characteristics of the patients regarding EAM, 
treatment response as well as clinical activity in patients 
with axSpA. The study will contribute to the under-
standing of the important role of central pain components 
in patients with axSpA by determining the prognostic 
value of PDQ score regarding treatment response. We 
will describe the relationship between central sensiti-
sation and subsequent treatment outcome. Knowledge 
about the presence of a neuropathic pain component 
may be particularly important to the rheumatologists 
treating patients  with axSpA, since the road to biolog-
ical treatment is short and a high BASDAI score primarily 
derived from patient-reported information. Identifying 
which patients  with axSpA who are likely to benefit from 
biologics (eg, TNF-α inhibitors) therapy is important, 
especially in view of the costs and potential side effects of 
these agents.
We anticipate (and hope) that this study can contribute 
to set focus on the need of treating the underlying pain 
mechanisms which not can be explained by inflammatory 
genesis in patients  with axSpA. The patients will prob-
ably have a better prognosis, if they are educated in and 
informed of all the various factors (ie, EAM and comor-
bidities) that can influence on the overall quality of life 
and treatment response. IBD is a frequent EAM among 
patients  with SpA and is important to take into account 
regarding treatment strategy, as NSAIDs increases the 
risk of flare in IBD. Using calprotectin measurements in 
stool and serum in this study may provide a promising 
strategy to identify patients with axSpA at risk of bowel 
inflammation and could play a role in overall patient 
stratification.
We know there is a higher prevalence of comorbidities 
in patients with inflammatory joint diseases compared 
with the general population,46 47 but the patients may 
receive suboptimal medical treatment for the comorbid-
ities compared with the general population, possibly due 
to the focus on their rheumatic diseases or because the 
lack of consensus of which health professional should 
take the responsibility for the patient as a whole. In this 
study, we outline the patient’s comorbidities which are 
in accordance with EULAR proposal regarding points to 
consider to collect comorbidities in patients with chronic 
inflammatory rheumatic diseases.48
The study may be limited by sample size possible, based 
on the anticipation that these patients (with axSpA) repre-
sent a heterogeneous population which may limit our 
ability to infer from the analyses.
In conclusion, the results of this study may add knowl-
edge to the current black box of complexities around 
disease measures and prognosis and the efficacy of 
biologics among patients diagnosed with axSpA. Hope-
fully, this project will facilitate a more efficient use of 
expensive drugs as well as multidisciplinary rehabilitation, 
by revealing the need for a more individualised biopsy-
chosocial model in the future management strategy.
ethIcS And dISSeMInAtIon
The study has been approved by the Region of Southern 
Denmark’s Ethics Committee with identification number 
S-20160094. Signed informed consent will be obtained 
from all participants. The study is registered at  Clini-
caltrials. gov (NCT02948608). We aim to disseminate 
the results of the proposed study through international 
conferences and international peer-reviewed journal(s).
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